Syngene International vs Peers
- Market cap
- ₹14,468 crore
- P/E
- 65.5
- P/B
- 2.99
- ROE
- 6.6%
- Dividend yield
- 0.35%
Syngene International ranks 2nd by market capitalisation among 4 Healthcare Research, Analytics & Technology companies tracked by ATS. Its largest peers are Indegene, Suven Life Sciences and Bilcare. Its P/E of 65.5 compares with a peer median of 28.8.
Syngene International vs Healthcare Research, Analytics & Technology peers
Sorted by market capitalisation.
| Company | Close (₹) | 1D | Market cap (₹ cr) | P/E | P/B | ROE | 1Y return |
|---|---|---|---|---|---|---|---|
| Indegene | 606.00 | +1.63% | 14,576 | 36.4 | 4.64 | 13.9% | +12.5% |
| Syngene International | 360.10 | -0.85% | 14,468 | 65.5 | 2.99 | 6.6% | +22.0% |
| Suven Life Sciences | 307.05 | -0.68% | 8,098 | 22.5 | 13.69 | -78.8% | +12.5% |
| Bilcare | 94.75 | +1.99% | 223 | 28.8 | 1.13 | 0.8% | +12.5% |
Source: NSE end-of-day prices; ratios from company filings. Data as of 7 October 2026. How this data is compiled.
Syngene International peer comparison — frequently asked questions
Who are Syngene International's competitors?
Syngene International's listed peers in Healthcare Research, Analytics & Technology include Indegene, Suven Life Sciences and Bilcare, ranked here by market capitalisation.
How does Syngene International's P/E compare with its peers?
Syngene International trades at a P/E of 65.5, against a median of 28.8 across the 3 Healthcare Research, Analytics & Technology peers shown.
Which is the largest company among Syngene International's peers?
By market capitalisation, the largest company in the group is Indegene at ₹14,576 crore, against ₹14,468 crore for Syngene International.
Same Data For Peers
Trade Syngene International With ATS
Track SYNGENE live and place orders from the Pocket app or the Pocket Web terminal with an ATS trading and demat account.
Figures are for information only and are not investment advice or a recommendation to buy, sell or hold any security. Investments in securities are subject to market risks; read all related documents carefully before investing.